Fig. 3From: Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label studyKidney disease severity status (eGFR slope) shift from pre-switch to post-switch (efficacy population). Fast-progressing: eGFR slope < − 5 mL/min/1.73 m2/year [4]. Progressing: eGFR slope ≥ − 5 to < − 3 mL/min/1.73 m2/year. Stable: eGFR slope ≥ − 3 mL/min/1.73 m2/year. eGFR estimated glomerular filtration rateBack to article page